Whole-Body irradiation increases the magnitude and persistence of adoptively transferred t cells associated with tumor regressionin a mouse model of prostate cancer

Cancer Immunology Research

Volumn 2, Issue 8, 2014, Pages 777-788

  Ward Kavanagh, Lindsay K ^a   Zhu, Junjia ^a,b   Cooper, Timothy K ^a   Schell, Todd D ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD8+ T LYMPHOCYTE; DISEASE MODEL; IMMUNOLOGY; LYMPH NODE; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; SPLEEN; TRANSGENIC MOUSE; WHOLE BODY RADIATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; SPLEEN; WHOLE-BODY IRRADIATION;

EID: 84925510797     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0164     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22.
3. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, et al. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009; 69:6256-64.
4. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121:1361-72.
5. Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, et al. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 1999; 29:1127-38.
6. de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, et al. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol 2008; 181:2563-71.
7. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007; 178:1268-76.
8. Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN. Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 2013; 191:3232-9.
9. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92:3439-43.
10. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a preclinical transgenic mouse model. Prostate 2003; 55:219-37.
11. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35:66-75.
12. Zheng X, Gao JX, Zhang H, Geiger TL, Liu Y, Zheng P. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 2002; 169: 4761-9.
13. + T lymphocytes. Science 2008; 319:215-20.
14. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011; 35: 123-34.
15. Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, et al. Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate 2012; 72: 514-22.
16. + T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 2009; 183:4848-52.
17. + T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A 2008; 105: 13003-8.
18. de Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM, et al. Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 2008; 181:5128-36.
19. + T cells via dendritic cell activation. J Immunol 2012; 189:558-66.
20. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-21.
21. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71.
22. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Cur Opin Immunol 2009; 21:233-40.
23. + T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol 2008; 181:4406-17.
24. Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol 1999; 73:5981-93.
25. Mueller SN, Heath W, McLain JD, Carbone FR, Jones CM. Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. Immunol Cell Biol 2002; 80:156-63.
26. Tevethia SS, Greenfield RS, Flyer DC, Tevethia MJ. SV40 transplantation antigen: relationship to SV40-specific proteins. Cold Spring Harbor Symp Quant Biol 1980; 44(Pt 1):235-42.
27. Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, et al. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol 2012; 40:5-17.
28. + T-cell response in vivo. Immunol Cell Biol 2010; 88:157-64.
29. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-93.
30. + T cells via TLR4 signaling. J Clin Invest 2007; 117:2197-204.
31. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23.
32. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9.
33. + T cells. J Exp Med 2005; 202:907-12.
34. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192:557-64.
35. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000; 192:549-56.
36. Murali-Krishna K, Ahmed R. Cutting edge: naive T cells masquerading as memory cells. J Immunol 2000; 165:1733-7.
37. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008; 68:1319-29.
38. Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, et al. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy 2012; 4:373-82.
39. Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, et al. Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol 2012; 189: 3936-46.
40. Higham EM, Shen CH, Wittrup KD, Chen J. Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J Immunol 2010; 184:5954-8.
41. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8:369-80.
42. + T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84.
43. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev 2014; 257:264-76.
44. + T cells. J Clin Invest 2005; 115:1616-26.
45. + memory stem cells. Nat Med 2009; 15:808-13.
46. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14.
47. + T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype. PLoS ONE 2012; 7:e41074.
48. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7.